### Midazolam

**Section:** 2. Medicines for pain and palliative care > 2.3. Medicines for other common symptoms in palliative care

#### Essential medicine status

- **Indication:** Palliative care  
  - **ICD11 code:** QC7A

- **INN:** Midazolam  
- **Medicine type:** Chemical agent  
- **List type:** Core

#### Formulations

- **Oral > Liquid:** 2 mg per mL oral liquid (EMLc)
- **Oral > Solid:** 7.5 mg solid oral dosage form; 15 mg solid oral dosage form
- **Parenteral > General injections > unspecified:** 1 mg per mL injection; 5 mg per mL injection

#### EML status history

- First added in 2009 ([TRS 958](https://example.com))
- Changed in 2013 ([TRS 985](https://example.com))

#### Sex

- All

#### Age

- Also recommended for children

#### Therapeutic alternatives

- The recommendation is for this specific medicine

#### Patent information

- Patents have expired in most jurisdictions
- [Read more about patents.](https://example.com)

#### Wikipedia

- Midazolam

#### DrugBank

- Midazolam

---

**Summary of evidence and Expert Committee recommendations**

Following a review of medicines for palliative care by the Expert Committee in 2013, midazolam was added to the EML for use in the management of anxiety, agitation and delirium in patients receiving palliative care. Additional oral dose forms were added to the EMLc.